Media Room Menu
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 5, 2018Industry executive adds considerable financial expertise as audit committee chairperson
-
Sep 4, 2018
-
Sep 3, 2018- First therapeutic approved for the treatment of aTTP, a rare blood-clotting disorder
-
Jul 31, 2018- Provention strengthens its strategic platform in type 1 diabetes (T1D) interception and prevention
-
Jul 30, 2018Nearly 70 million doses to be manufactured this season
Jul 2, 2018- Company invests €66 million in Chengdu, Sichuan province, China-
Jun 25, 2018- Toujeo (insulin glargine injection 300 Units/mL) met primary endpoint in lowering blood sugar levels and was non-inferior to insulin degludec in adults with type 2 diabetes not previously on insulin